Objectives. To determine the distribution of HLA-DR type and FcRIIa/IIIa polymorphisms, and to analyse the combined effects of these genes for susceptibility in Korean systemic lupus erythematosus (SLE) patients. Methods. A total of 299 SLE patients meeting 1982 ACR criteria and 144 Korean disease-free controls were enrolled. Genotyping for the FcRIIa 131 R/H and FcRIIIa 176 F/V was performed by polymerase chain reaction (PCR) of genomic DNA using allele-specific primers. HLA-DRB1 typing was performed by the PCR-SSOP method.
screens in SLE families and these screens have identified six regions meeting criteria for significant linkage (LOD score >3.3) [4] [5] [6] [7] [8] [9] . Using several animal models of SLE and genetic dissection, similar candidate genes or gene families responsible for susceptibility to SLE in both mouse and humans were suggested [10] [11] [12] [13] [14] . Candidate gene approaches in both population association and family linkage studies have been widely used and thus there are hundreds of published studies. Despite several potential difficulties such as population admixture and genetic drift, this association study has the significant advantage over the other strategies of having greater power to detect small effects [3, 15, 16] . Among these candidate genes, the HLA region, complement components and low-affinity receptors for IgG showed significant association with SLE susceptibility [3, 15] .
HLA genes have received significant attention in human SLE, and there is evidence supporting a role for specific extended HLA haplotypes as genetic risk factors for disease expression in several populations [17] [18] [19] [20] [21] . HLA-DR2 and -DR3 have shown consistent associations with SLE in European Caucasian populations [22] . In Korea, significant increased frequency of HLA-DRB1*1501 to DRB5*0101, and DR9 was reported in SLE patients [23, 24] . These HLA regions also showed stronger association with autoantibody production in SLE than with disease expression itself [22] . Although the precise genes attributed to these associations are not known, genome-wide scan studies have indicated that this MHC region is a very important gene location for susceptibility to SLE [4, 5, 9] . Recent studies have shown that Fc receptors (FcR) could be one of the non-MHC susceptibility genes for SLE [4, [25] [26] [27] [28] . FcRIIa and IIIa are located within the same cluster in chromosome 1q21-23 and they have allelic variants which differ substantially in their functional capacities of immune complex clearance. FcRIIa alleles, R131 and H131, differ at amino acid position 131 in the extracellular domain and also differ in their ability to bind human IgG2: R131 is the low-binding allele, H131 is high binding and heterozygotes have intermediate function. FcRIIIa alleles, F176 and V176, which differ in one amino acid at position 176 in the extracellular domain and differ in their ability to bind human IgG1 and IgG3: F176 is the low-binding allele, V176 is high binding. Although there are a few reports about linkage disequilibrium (LD) between FcRIIa and IIIa in other ethnic groups, there have been no reports to date in Korean populations.
We have previously reported that FcRIIa-R131 homozygote and R131 allele were predisposing factors for SLE development [29] . Recently, the importance of epistasis and epistatic interaction between two susceptibility alleles in multigenic diseases such as SLE has been emphasized in genetic pathogenesis based on various genetic studies. Thus we studied whether the epistatic effect between HLA-DR and FcRIIa/IIIa among the many important candidate genes in SLE was observed in Korean patients with SLE.
Patients and methods
A total of 299 Korean patients meeting the American College of Rheumatology (ACR) criteria for SLE [30] were recruited from eight rheumatology departments based in university hospitals throughout the country. A disease-free control group consisted of 144 medical students and laboratory workers from Hanyang University medical centre. All SLE patients and control subjects were ethnically matched Koreans. Written informed consent was obtained from each subject. Patients were classified as having nephritis if they fulfilled the ACR criteria for renal involvement. The other major organ involvement was defined according to the criteria of the ACR. Clinical and laboratory data including sex, age, age of the first symptom onset, age at the time of clinical diagnosis and ACR diagnosis were obtained retrospectively from the medical record. Testing for antinuclear antibodies (ANA) was carried out by indirect immunofluorescence using IT-1 cells; C3 and C4 by nephelometry (Beckman, USA); anti-double-stranded DNA antibody by radioimmunoassay or Crithidia lucillae assay; anti-Sm, -Ro, -La and -nRNP by double immunodiffusion; and anticardiolipin antibody (aCL) by ELISA. We used the lowest complement values and the highest value for the amount of daily proteinuria.
FcRIIa/IIIa genotyping and FcRIIIa genomic DNA sequencing
For genotyping of FcRIIa and FcRIIIa, DNA was isolated from peripheral blood (Puregene kit, Gentra systems, Minneapolis, MN) and polymerase chain reaction (PCR) was performed as previously described [29, 31, 32] . To confirm the FcRIIIa genomic sequence of 17 individuals whose PCR results were inadequate, PCR was done with primers to amplify a portion of exon 4 of FcRIIIa which corresponds to EC2 [29, 32] . PCR products were purified by Qiagen Column (Qiagen, Germany) and genomic DNA sequencing was performed on an ABI PRISM 310 (Perkin Elmer, USA).
HLA-DRB1 typing
HLA-DRB1 typing was performed by the PCR-SSOP method, which was essentially the same as that described at the 12th International Workshop, with minor modifications [33] . Specific HLA-DRB1 primers were used to amplify DRB1 products, which were then denatured and immobilized on a nylon membrane and probed with a series of digoxigeninlabelled oligonucleotides specific for the known hypervariable sequences. Stringent washing was performed in the presence of tetramethyl ammonium chloride (TMAC, Sigma chemical Co., St. Louis, USA). The hybridized probe was detected according to the manufacturer's instructions with the anti-digoxigenin antibody conjugated with alkaline phosphatase, followed by addition of chemiluminescent substrate CSPD (Boehringer Mannheim, GmbH, Germany). Chemiluminescence was detected by exposing to radiographic film.
Statistical analysis
The distribution of the allele and genotype of FcRIIa, FcRIIIa and HLA-DRB1 between two groups (SLE patients vs controls, SLE with nephritis vs SLE without nephritis, SLE with nephritis vs controls) was compared with 3 Â 2 or 2 Â 2 contingency tables using the 2 -test. We used the EH program for haplotype analysis [34, 35] Linkage disequilibrium between FcRIIa and FcRIIIa was assessed using the D value for non-random assortment of alleles [36] . To observe the additive effect of FcRIIa/IIIa and HLA-DRB1 on the development of SLE or lupus nephritis, groups with both risk alleles were compared with reference groups without both risk alleles using 2 . We applied corrected P values to this multiple testing [37] . In brief, when an initial 2 Â C contingency table is partitioned into nonindependent 2 Â 2 tables, the value of corrected a 0 is obtained as follows: a 0 ¼ a/2(C -1). The value of C in our multiple testing is 4.
A probability of 0.05 (2-tailed) was used to reject the null hypothesis that there was no difference in the distribution of allele and genotype between the groups. Odds ratios with 95% confidence intervals (95% CI) were calculated from 2 Â 2 contingency tables by 2 -test. The mean age at onset and age of clinical and ACR diagnosis were compared using independent sample t-test or ANOVA, and the amount of proteinuria using the Mann-Whitney U-test or Kruskal-Wallis test. Here we used SPSS 10.0 for Windows for statistical analysis.
Results

Baseline characteristics
We used the same data for SLE patients that we used in our previous report [29] . These are summarized in Table 1 .
Distribution of FcRIIa and FcRIIIa between SLE patients and controls
There was significant skewing in the distribution of the three FcRIIa genotypes between the SLE patients and the controls, but not in FcRIIIa genotypes (Table 2) : FcRIIa R/R131 homozygote was a significant predictor of SLE [P ¼ 0.002 for R/R131 vs R/H131 and H/H131, OR 2.6 (95% CI 1.3-5.2)], but FcRIIa R131 allele (R/R131 or R/H131) was not. The frequency of any genotype and allele of both FcRIIa and IIIa was not significantly different between SLE with nephritis and SLE without nephritis, and between SLE with nephritis and controls.
To analyse the protective effect of haplotype including high-binding alleles or to analyse the susceptibility of disease of haplotype including low-binding alleles of FcRIIa and IIIa, we observed the frequency of FcRIIa/FcRIIIa haplotype R131/F176, R131/V176, H131/F176, H131/V176 in SLE with or without nephritis and controls. In this analysis, we observed that the high-binding allele combination H131/V176 showed a protective effect for the development of lupus nephritis [P ¼ 0.018 for H131/V176 vs R131/F176, R131/V176, and H131/F176, relative risk (RR) 0.6 (95% CI 0.4-0.9)], but the low-binding allele combination R131/F176 was not associated with SLE and SLE nephritis ( Table 2) . Testing for the presence of LD between alleles at the two FcR loci showed no significant association
Distribution of HLA-DR type between SLE patients and controls Table 3 ). The frequency of HLA-DRB1*01 and *04 allele was lower in SLE patients than controls. With respect to clinical manifestations and autoantibody profiles of SLE, the frequencies of neurological disorder and anti-RNP antibody in SLE patients with HLA-DRB1*15 allele were significantly increased compared with controls (Table 4) . Besides HLA-DRB1*15, the other HLA-DR types were also associated with some clinical manifestations or laboratory findings. Increased frequency of arthritis and bacterial infection in patients with HLA-DRB1*04, increased serum creatinine level in patients with HLA-DRB1*01, haemolytic anaemia in patients with HLA-DRB1*13 or DRB1*07, anti-RNP antibody in patients with HLA-DRB1*11, anti-La antibody in patients with HLA-DRB1*07 or DRB1*08, lupus anticoagulant in patients with HLA-DRB1*12, and Raynaud's phenomenon and low C4 in patients with HLA-DRB1*09 were observed ( Table 4) .
Interaction of the FcRIIa and HLA-DR polymorphism in the risk of SLE
To evaluate the combined effect of the FcRIIa and HLA-DR polymorphism, we calculated the risk of developing SLE conferred by either the FcRIIa-R/R131 genotype or HLA-DRB1*15 allele, and then calculated the risk conferred by both high-risk genes together [25, 38, 39] (Table 5 ). At first, the risk associated with the presence of the HLA-DRB1*15 allele (homozygote or heterozygote) in the absence of the FcRIIa-R/R131 genotype compared with the reference group with neither FcRIIa-R/R131 nor HLA-DRB1*15 allele was determined. The risk was statistically significant in SLE patients [RR ¼ 2.1 (1.2-3.7), corrected P < 0.008]. Similarly, the effect of the FcRIIa-R/R131 homozygote in the subgroup of individuals who were HLA-DRB1*15 allele negative was statistically significant [RR ¼ 5.3 (1.9-15.4), corrected P < 0.001]. The corrected P value of the above partitioning 2 Â 2 comparison test was 0.05 and 0.006, respectively. The combined effect of these two polymorphic genes was then calculated, but individuals with both genes did not show a significant increase in SLE development compared with the reference group with neither FcRIIa-R/R131 nor HLA-DRB1*15 allele (Table 5) .
Discussion
SLE is a disease of polygenic inheritance and therefore interactions between candidate genes that participate in separate genetic pathways in SLE pathogenesis may be important [3] . Based on genome-wide scans, animal studies and many association studies, a multitude of candidate genes have been noticed recently [4, 5] . They contain genes related to triggering the loss of immune tolerance to nuclear autoantigens and mediating the initiation of autoimmunity. Also genes participating in the disruption of the normal immune system and genes mediating specific organ damage were important in SLE pathogenesis. These genes may co-operate in the development of SLE in concert [3] . FcR genes in chromosome 1q23 and MHC class II genes in chromosome 6p are among candidate genes of SLE. There are various proposals for the mechanism underlying the higher association of these polymorphisms in SLE patients. HLA class II molecules elicit the T-helper cell response after presentation of specific antigens by antigen-presenting cells. Therefore, autoantibody production mediated by T-helper cells specific to autoantigens, a characteristic feature in SLE, can be attributed to HLA class II molecules [3, 40] . The role of FcR polymorphisms in the pathogenesis of SLE has been focused on their dysregulation of immune complex handling and enhanced immune complexmediated organ injury [25, 38, 39] . Despite this reasonable theoretical background and many positive results, a significant debate in interpreting these association data is posed by the significant LD across the region. In fact, reported associations of SLE with several MHC class III genes such as TNF-, TAP genes, HSP70 and complement genes as well as DQ alleles may reflect LD with HLA-DR allele or the epistatic effects of several genes on extended haplotypes [41] [42] [43] [44] [45] . Also, the Fc receptors are very tightly clustered at 1q23, and the interpretation of the association result of one locus is potentially complicated by LD in the region [25, 38, 46] . This study showed similar results to previous reports on Korean populations: FcRIIa-R/R131 homozygote and HLA-DRB1*15 allele were significantly prevalent in SLE patients, but not FcRIIIa polymorphism or HLA-DR3 [23, 24, 29] . In addition, several non-HLA-DRB1*15 alleles were associated with some clinical manifestations and some autoantibodies as shown in Table 4 . Among these associations, increased frequency of arthritis in patients with HLA-DR4-which has been reported as a susceptible allele in rheumatoid arthritiswas interesting and suggested that HLA-DR4 allele participates in the development of arthritis in SLE as in RA. We further analysed the effects of FcRIIa polymorphism on arthritis in SLE patients. There was no association between the two variables (data not shown). Although we showed there are many associations between various HLA-DRB1 alleles and clinical We analysed the combined effects of both candidate genes on SLE, HLA-DRB1 and FcRIIa-R/R131. HLA-DRB1*15 allele was a significant predictor of SLE in FcRIIa-R/R131 homozygote-negative individuals, and FcRIIa-R/R131 homozygote vice versa. Also, ORs of HLA-DRB1*15 and FcRIIa-R/R131 homozygote for SLE in FcRIIa-R/R131 homozygote-negative and HLA-DRB1*15-negative individuals, respectively, are more increased than initial ORs in total individuals. These results suggest that the two susceptible genes may not have an additive or synergistic effect on OR for SLE, but rather each gene has independent association with SLE. Also one candidate gene may have a more pathogenic role, especially within the individuals without the other susceptible gene, suggesting HLA-DRB1 and FcRIIa are probably involved in different pathogenic pathways. There are a few reports that have analysed the association of these two genes in SLE development. Manger et al. [25] analysed the distribution of FcRIIa polymorphism and HLA-DR3 in Caucasian SLE patients. Although they did not present the data in detail, they suggested that HLA-DR3 haplotypes did not seem to represent additional risk factors for the association of the FcRIIa-R131 allele polymorphism with SLE. We also obtained the results about LD between FcRIIa and FcRIIIa in Korean populations, which showed no significant associations. These results were consistent with other ethnic groups [28] .
In addition, we analysed the combination effect between HLA-DRB1*07 and FcRIIa polymorphism, and HLA-DRB1*15 and FcRIIIa polymorphism, and obtained no significant combination effects (data not shown).
Our study had some limitations to interpretation. Control groups were ethnically matched with SLE patients, but not sex and age matched. Also the size of the control group was too small to conclude the exact role of the combination of two candidate genes in SLE susceptibility.
In conclusion, our results suggest that FcRIIa-R/R131 homozygote and HLA-DRB1*15 allele are independent risk factors in Korean SLE patients without additive and synergistic effects.
